FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 577 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Soaring skin cancer cases hit a record high July 7, 2023 Population-based lung cancer screening can reduce mortality in people who have... March 27, 2026 Immune cell count could determine whether chemotherapy is required in oropharyngeal... May 2, 2022 Is AI Ready to Play a Leading Role in Colorectal Cancer... October 10, 2023 Load more HOT NEWS FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... Financial Navigation Can Reduce the Financial Toxicity of Cancer Care Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and...
